Progyny (PGNY) has launched Progyny Select, a fully insured supplemental fertility and women’s health plan targeting small U.S. employers with fixed premium pricing, drawing investor attention to a new potential demand pool.

The 11.17% 7 day share price return suggests traders are reacting positively to Progyny Select. However, the 90 day share price return of 26.10% and 3 year total shareholder return of 47.69% indicate longer term momentum has been weak.

If this kind of product launch has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 35 healthcare AI stocks

With the shares at US$18.12, a value score of 4, an intrinsic discount indication of 74.11% and a 51.52% gap to the average analyst target, you have to ask: is there real upside here, or is the market already factoring in future growth?

Most Popular Narrative: 41.4% Undervalued

With Progyny last closing at $18.12 against a narrative fair value of $30.91, the current share price sits well below that central estimate, framing a wide gap that the most followed narrative tries to explain.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross-sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Curious what kind of revenue build, profitability lift, and future earnings multiple are baked into that $30.91 figure? The narrative leans on sustained demand, richer margins, and a premium valuation profile to bridge the gap between today’s price and its fair value line.

Result: Fair Value of $30.91 (UNDERVALUED)

However, you still need to weigh employer cost cutting, which could slow adoption of premium benefits, and ongoing regulatory scrutiny around reproductive health that may curb Progyny’s addressable market.

Another Valuation Check Using Earnings Multiples

The SWS model says Progyny trades at a P/E of 24.3x versus a fair ratio of 22x, the US Healthcare industry on 23x and close peers on 31.2x. That mix of slightly rich versus fair ratio but cheaper than similar names raises a simple question: is this a margin of safety or a premium in disguise?

Next Steps

Given the mix of cautious questions and clear optimism in this review, it makes sense to check the numbers yourself and pressure test the thesis. To see what investors are excited about, take a closer look at the 3 key rewards

Looking for more investment ideas?

If Progyny has you thinking bigger about your portfolio, do not stop here. Broaden your watchlist with a few focused idea pools tailored to different objectives.

• Target potential mispricing by scanning 59 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect them yet.
• Prioritize resilience by reviewing 70 resilient stocks with low risk scores that score well on stability so sharp swings are less likely to dominate your returns.
• Hunt for fresh opportunities by checking the screener containing 23 high quality undiscovered gems before the crowd starts paying closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.